{"id":"W2132784721","doi":"10.1136/gutjnl-2011-301668","title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","year":2012,"lang":"en","type":"article","venue":"Gut","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1495,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University","funders":"Novartis Institutes for BioMedical Research; National Institutes of Health","keywords":"Secukinumab; Placebo; Medicine; Internal medicine; Clinical endpoint; Adverse effect; Crohn's disease; Confidence interval; Randomized controlled trial; Gastroenterology; Disease; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02124235727899869,"score_gpt":0.3076641879383812,"score_spread":0.2864218306593825,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}